SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals Inc (SNDX) is not a strong buy for a beginner, long-term investor at this time. While the stock is oversold based on RSI and has positive long-term growth potential in its pipeline, the technical indicators, options sentiment, and financial performance suggest caution. The lack of immediate positive catalysts and the current downtrend make it less appealing for immediate investment.
The stock is in a downtrend with MACD negatively expanding (-0.406) and RSI at 14.471, indicating oversold conditions. The price is near key support levels (S1: 21.626, S2: 20.624), but moving averages are converging, showing no clear upward momentum.
Analysts have maintained positive ratings with increased price targets, reflecting confidence in the company's pipeline, particularly for Revuforj and Niktimvo. Revenue growth in Q4 2025 was significant, up 794.90% YoY.
The stock is in a technical downtrend with a high probability of further short-term declines (-3.56% in the next week, -8.95% in the next month). Financial metrics like net income (-27.77% YoY) and EPS (-28.44% YoY) have declined. No recent news or congress trading data suggests a lack of immediate catalysts.
In Q4 2025, revenue increased significantly by 794.90% YoY to $68.73M, but net income dropped by -27.77% YoY to -$68.01M, and EPS fell by -28.44% YoY to -0.78. Gross margin improved to 96.06%, up 7.64% YoY.
Analysts remain bullish with Buy/Outperform ratings and price targets ranging from $28 to $57. Recent updates highlight confidence in the company's pipeline, particularly for Revuforj and Niktimvo, but price targets have been adjusted downward by some firms.
